The art of killing: Double stroke with apoptin and survivin as a novel approach in cancer therapy

Cancer Biology and Therapy

Volumn 7, Issue 7, 2008, Pages 1061-1062

  Panigrahi, Soumya ^a,b   Klonisch, Thomas ^a   Los, Marek ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c BioApplications Enterprises Winnipeg   (Canada)

Author keywords

Apoptin; Brevinin 2R; Cancer therapy; Hamlet; IAPs; R4orf4; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTIN; MICRORNA; SURVIVIN;

ANTISENSE THERAPY; CANCER GENE THERAPY; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; DNA REPAIR; DNA SYNTHESIS; GENE EXPRESSION; GENETIC TRANSCRIPTION; NOTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING;

EID: 47949106855     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.7.6492     Document Type: Note

References (21)

1. Houshmand P, Zlotnik A. Targeting tumor cells. Curr Opin Cell Biol 2003; 15:640-4.
2. Krzemieniecki K, Szpyt E, Rashedi I, Gawron K, Los M. Targeting of Solid Tumors and Blood Malignancies by Antibody-Based Therapies. Centr Eur J Biol 2006; 1:167-82.
3. Maddika S, Mendoza FJ, Hauff K, Zamzow CR, Paranjothy T, Los M. Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer Biol Ther 2006; 5:10-9.
4. Mok KH, Pettersson J, Orrenius S, Svanborg C. HAMLET, protein folding and tumor cell death. Biochem Biophys Res Commun 2007; 354:1-7.
5. Liu Q, Fu H, Xing R, Tie Y, Zhu J, Sun Z, Zheng X. Survivin knockdown combined with apoptin overexpression inhibits cell growth significantly. Cancer Biol Ther 2008; 7.
6. Silke J, Vaux DL. Two kinds of BIR-containing protein - inhibitors of apoptosis, or required for mitosis. J Cell Sci 2001; 114:1821-7.
7. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases and anticancer drugs. Cancer Res 1998; 58:5315-20.
8. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC, Altieri DC. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999; 1:461-6.
9. Chen J, Wu W, Tahir SK, Kroeger PE, Rosenberg SH, Cowsert LM, Bennett F, Krajewski S, Krajewska M, Welsh K, Reed JC, Ng SC. Downregulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2000; 2:235-41.
10. Los M, Burek CJ, Stroh C, Benedyk K, Hug H, Mackiewicz A. Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discov Today 2003; 8:67-77.
11. Danen-Van Oorschot AA, Fischer DF, Grimbergen JM, Klein B, Zhuang S, Falkenburg JH, Backendorf C, Quax PH, Van der Eb AJ, Noteborn MH. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc Natl Acad Sci USA 1997; 94:5843-7.
12. Backendorf C, Visser AE, de Boer AG, Zimmerman R, Visser M, Voskamp P, Zhang YH, Noteborn M. Apoptin: therapeutic potential of an early sensor of carcinogenic transformation. Annu Rev Pharmacol Toxicol 2008; 48:143-69.
13. Burek M, Maddika S, Burek CJ, Daniel PT, Schulze-Osthoff K, Los M. Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1 dependent. Oncogene 2006; 25:2213-22.
14. Danen-van Oorschot AA, van Der Eb AJ, Noteborn MH. The chicken anemia virus-derived protein apoptin requires activation of caspases for induction of apoptosis in human tumor cells. J Virol 2000; 74:7072-8.
15. Maddika S, Booy EP, Johar D, Gibson SB, Ghavami S, Los M. Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. J Cell Sci 2005; 118:4485-93.
16. Maddika S, Bay GH, Kroczak TJ, Ande SR, Maddika S, Wiechec E, Gibson SB, Los M. Akt is transferred to the nucleus of cells treated with apoptin, and it participates in apoptin-induced cell death. Cell Prolif 2007; 40:835-48.
17. Maddika S, Wiechec E, Ande SR, Poon IK, Fischer U, Wesselborg S, Jans DA, Schulze-Osthoff K, Los M. Interaction with PI3-kinase contributes to the cytotoxic activity of Apoptin. Oncogene 2007; 27:3060-5..
18. Poon IK, Oro C, Dias MM, Zhang J, Jans DA. Apoptin nuclear accumulation is modulated by a CRM1-recognized nuclear export signal that is active in normal but not in tumor cells. Cancer Res 2005; 65:7059-64.
19. 2/M arrest and apoptosis in the absence of p53. Genes Dev 2004; 18:1952-7.
20. Leliveld SR, Dame RT, Mommaas MA, Koerten HK, Wyman C, Danen-van Oorschot AA, Rohn JL, Noteborn MH, Abrahams JP. Apoptin protein multimers form distinct higher-order nucleoprotein complexes with DNA. Nucleic Acids Res 2003; 31:4805-13.
21. Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K, Sato M, Sato N. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 2005; 65:11018-25.